Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CCR5 antibody and to the pharmaceutical use of said conjugate.

Abstract: The current invention is related to a conjugate comprising two or more antifusogenic peptides and an anti-CD4 antibody (mAb CD4) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said anti-CD4 antibody and to the pharmaceutical use of said conjugate.

Abstract: According to one aspect of the present invention, a razor cartridge includes an outer shell, and a support structure. The outer shell defines a primary blade opening and a trimming blade opening. The support assembly is located at least partially inside the outer shell and includes at least one primary blade slot and a trim blade slot. A primary blade is located within each of the primary blade slots in the support assembly such that a cutting edge on the primary blade extends through the primary blade opening in the outer shell. A trim blade is located within the trim blade slot in the support structure such that a cutting edge on the trim blade extends through the trim blade opening in the outer shell.

Abstract: A razor cartridge is provided with a skin engaging structure at the cap and/or guard surface of the razor cartridge. The skin engaging structure has an array of closely spaced elongated protrusions integrally formed with a substrate. In use, the protrusions produce a pleasant tactile sensation tending to reduce shaving discomfort. The protrusions are formed by closely packed molded flexible filaments that can be less than 0.25 mm wide and have spacing between adjacent protrusions less than 0.2 mm. The protrusions can have a density greater than 5 protrusions per mm2. The skin engaging structure can be molded from e.g. an olefin polymer. The substrate can be integrally formed with a housing of the razor cartridge.

Abstract: According to one aspect of the present invention, a dispenser for one or more razor cartridges includes a base, two side walls, a front wall, a rear wall, a first divider, a second divider, a cover, and a side spring. The first divider is located between the front wall and the rear wall. The second divider is located between the first divider and the front wall, forming a chamber between the second divider and the first divider. The chamber is sized and shaped to receive at least a portion of a razor cartridge. The cover extends partially over the chamber between the first divider and second divider, and is sized to provide an opening through which the razor cartridge can be inserted into the chamber. The side spring extends widthwise into the chamber. The cover and the side spring frictionally engage the razor cartridge when inserted into the chamber.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Abstract: The present invention is a razor blade carrier having a base with at least two stepped protrusion extending outwardly therefrom. The stepped protrusion define at least two landing positions that support a portion of the razor blade. The landing surfaces of the stepped protrusions cooperate to define at least two razor blade locations. The razor blade carrier is used in a razor cartridge.